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In 1983, Karlsson et al. described a genetic polymorphism
associated with human urinary high molecular weight glyco-
proteins. In this, four components with different mobilities in
sodium dodecyl sulphate polyacrylamide (SDS PAGE) gels
were identified by their reaction with radioiodinated peanut
lectin and each individual was found to exhibit one or two
bands. Familial studies showed that the four alleles within
the system are inherited in a normal Mendelian fashion and
population analyses confirmed that the observed distribution
of phenotypes in normal individuals lies close to Hardy-
Weinberg predictions.
Subsequently, it was determined that the anti-breast
carcinoma monoclonal antibody, NCRC-l 1, like the related
anti-human milk fat globule antibodies, HMFG-1 and
HMFG-2 (Burchell et al., 1983) and the anti-tumour
antibody, Cal (which defines the Ca antigen found on a
range of human malignant cells - Ashall et al., 1982), also
reacted with a similar family of high molecular weight
glycoproteins which are present in the urine of all individuals
and in the sera of breast cancer patients (Swallow et al.,
1986; Price et al., 1987). In addition, these glycoproteins are
found on the luminal surfaces of glandular epithelia, on milk
fat globule membranes and associated with most epithelial
malignancies (Ellis et al., 1984).
It has been suggested that these high molecular weight
polymorphic glycoproteins, have a protective function in
their normal environment (e.g. stabilization of milk fat
emulsions in the digestive tract until milk fat is hydrolysed
by lipases and absorbed in the intestine - Shimizu and
Yamauchi (1982) - or as a shield in the urothelium
providing protection to the underlying cells against low
urinary pH - Bramwell et al. (1983). If this is so, then it is
feasible that specific phenotypes of the antigen may be
associated with a particular susceptibility (or resistance) to
carcinogenic insult and/or transformation processes leading
to the onset of neoplasia. This proposal has been examined
in the present investigation by comparing the distribution of
NCRC-11 defined glycoprotein phenotypes in patients with
breast cancer with the distribution of phenotypes in a
comparable sex-matched healthy population.
Urine samples from advanced breast cancer patients with
progressive disease and from malignant disease-free female
controls (laboratory personnel and out-patients at the
University Hospital, Nottingham) were stored at -20°C
until use. Urine samples were concentrated approximately
15-fold by dialysis against Aquacide II (Calbiochem, Los
Angeles, CA). A panel of concentrated urine samples of
defined peanut lectin binding-phenotype was kindly provided
by D. Swallow and B. Griffiths (MRC Human Biochemical
Genetics Unit, University College, London), and these were
employed as standards for phenotype designation.
Concentrated urine samples were diluted 1:1 in reducing
sample buffer (10% glycerol, 2% SDS, 5% ,B-mercapto-
ethanol, 0.001% bromophenol blue in 0.064M Tris-HCI, pH
6.8). The samples were then applied to 5 to 15% gradient
polyacrylamide gels, with 3% stacking gels, which had been
pre-run for 15h at 50volt before use. Electrophoresis was
continued at 50volt for 15h using the discontinuous buffer
system of Laemmli (1970).
Electroblotting onto nitrocellulose membranes was per-
formed essentially as described by Towbin et al. (1979) using
the Biorad Transblot Apparatus for 20h at 50volt and
200mA in 25 mM Tris, 192 mM glycine buffer, pH 8.3,
containing 20% methanol. The membranes were blocked for
h at room temperature using 1% bovine serum albumin
(BSA) in PBS, pH 7.3, and then washed 6 times with PBS
over 30min. Incubation with the first antibody (neat NCRC-
11 hybridoma tissue culture supernatant) was carried out for
3h at room temperature and the membranes were washed as
before. Horse radish peroxidase conjugated to F(ab')2
fragments of sheep anti-mouse Ig (Amersham International,
Amersham, Bucks.) at a dilution of 1/1000 in 1% BSA in
PBS was applied to the nitrocellulose membranes and
incubated at room temperature for 1h. After washing 9
times with PBS over 45min, peroxidase activity was detected
by addition of 25mg of 3,3' diaminobenzidine tetrahydro-
chloride (3,4,3',4'-tetra-aminobiphenylhydrochloride - BDH,
Poole, Dorset) in 50ml 10mM Tris-HCI, pH 7.4 with 50pl
30% H202-
Figure 1 is an example of different phenotypes of urinary
glycoproteins defined by the NCRC-11 antibody. The
numbering system for the bands is as described by Karlsson
et al. (1983) with reference to a standard panel of urines of
known phenotype as defined by their reactivity with peanut
lectin. Each of the four possible bands is present in one or
more of these urine samples, with any individual displaying
one or two bands (i.e. homozygote or heterozygote
expression of gene products). In preliminary studies, it was
demonstrated that the phenotype of any patient's high
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Figure 1 Immunoblotting of 5 concentrated urine samples.
Samples were separated by SDS PAGE, electrophoretically trans-
ferred onto nitrocellulose paper and stained with the NCRC-l1
antibody. Staining was visualized by incubation with peroxidase
conjugated anti-mouse Ig followed by diaminobenzidine.
Positions of molecular weight marker proteins (mol.
wt x 10-3) and the top of the separating gel (open arrow) are
shown to the left of the gel. The designations of the individual
phenotypes according to Karlsson et al. (1983) are indicated to
the right.
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Table I Distributions of NCRC-1 1 antibody-defined phenotypes of urinary
glycoproteins in breast cancer patients and normal individuals
Breast cancer patients:
Observed gene frequencies for NCRC- 11 antibody defined urinary
glycoproteins (bands 1 to 4):
f(l)=0.34; f(2)=0.38; f(3)=0.21; f(4)=0.07
Distribution of phenotypes:
Phenotype 1 2-1 2 3-1 3-2 3 4-1 4-2 4-3 4 Total
Obs. no. 12 17 21 15 11 5 7 3 4 0 95
Exp. no.a 11.0 24.5 13.7 13.6 15.2 4.2 4.5 5.1 2.8 0.5 95
x2= 10.99; P>0.05
Normalfemale control subjects:
Observed gene frequencies for NCRC-11 antibody defined urinary
glycoproteins (bands 1 to 4):
f(l)=0.39; f(2)=0.37; f(3)=0.19; f(4)=0.05
Distribution of phenotypes:
Phenotype 1 2-1 2 3-1 3-2 3 4-1 4-2 4-3 4 Total
Obs. no. 6 20 7 7 5 4 3 1 1 0 54
Exp. no. 8.2 15.6 7.4 8.0 7.6 2.0 2.1 2.0 1.0 0.1 54
x2=5.88; P>0.05
aThe expected distribution was calculated from the observed gene
frequencies assuming Hardy-Weinberg equilibrium.
molecular weight urinary glycoproteins was identical to that
of glycoproteins produced by the tumour and found in the
circulation - NCRC-11 defined antigens have not been
detected at significant levels in the serum of normal
individuals either by immunoblotting or by radioimmuno-
assay (Price et al., 1987).
The phenotypes of NCRC-11 antibody-binding urinary
glycoproteins of 95 breast cancer patients and 54 normal
female control subjects were determined and the results are
summarized in Table I which also includes the gene
frequencies for the components in bands 1 to 4. The
expected distribution of phenotypes was calculated from the
observed gene frequencies assuming Hardy-Weinberg
equilibrium. In both the breast cancer patients and normal
individuals, the observed distribution did not deviate
significantly from the calculated expected distributions (in
accord with Hardy-Weinberg predictions for Mendelian co-
dominant inheritance). Furthermore, differences in the
distribution of phenotypes in the patient group in
comparison to those of the normal controls did not reach
statistical significance. Similarly, there was no significant
(P>0.05) preponderance of homozygote individuals in the
patient group compared with the controls, as might be
expected if diversity in NCRC- 1I antigens confers any
protective influence against neoplasia.
Clearly, for a more thorough investigation of the rarer
phenotypes, it would be necessary to increase the number of
samples analysed. However, it may be concluded from the
present findings that the genetic polymorphism of high
molecular weight glycoproteins identified using the NCRC-
11 antibody plays no major role in the occurrence of breast
cancer. Whether this system is of any influence in other
epithelial malignancies with which NCRC- 1I antigens are
associated, or whether this antigen system influences tumour
progression in any way, remains to be determined. The
finding that the degree of staining of primary breast tumours
with the NCRC- 1 antibody is associated with good
prognosis (Ellis et al., 1984) still requires explanation, and
the genetic polymorphism of the antigen involved is an
additional factor to be considered in evaluating its
prognostic capabilities.
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